OMass Therapeutics

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.